摘要
目的:观察过氧化物酶体增殖物激活受体γ(PPARγ)配体吡格列酮对糖尿病大鼠血清基质金属蛋白酶9(MMP-9)浓度和外周血单核细胞中MMP-9表达的影响。方法:40只Wistar大鼠随机分为5组,即对照组、糖尿病组和不同剂量5、10、20mg/(kg.d)吡格列酮治疗组,每组8只。给糖尿病组和3个吡格列酮治疗组大鼠腹腔注射链脲霉素制作糖尿病大鼠模型后,各吡格列酮治疗组以不同剂量的吡格列酮灌胃:5、10、20mg/(kg.d),共28d;对照组和糖尿病组以等量生理盐水灌胃。比较治疗前、后的血清MMP-9浓度的变化。分离大鼠外周血单核细胞,用RT-PCR和Westernblot检测MMP-9表达的变化。结果:与对照组比较,吡格列酮降低血清MMP-9的浓度(P<0.05),降低外周血单核细胞中MMP-9的表达。结论:吡格列酮可以降低糖尿病大鼠血清MMP-9浓度及外周血单核细胞中MMP-9的表达,提示其在降糖之外还具有心血管保护作用。
AIM： To observe the effect of pioglitazone on serum MMP-9 concentration and expression of peripheral monocyte MMP-9 in diabetic rats. METHODS： Forty Wistar rats were randomly divided into five groups： control group, diabetes group and three pioglitazone groups of 5, 10, 20 mg/（kg ~ d）, re- spectively. The rat diabetic model was made by IP injection of streptozocin. After the model was success- fully made, rats in pioglitazone group were treated with pioglitazone [5, 10 or 20 mg/（kg＂ d） ~28 days] JP by gavage and rats in the control group and diabetes group were treated with normal saline. Concentra- tions of serum MMP-9 were detected by ELISA. Expression of peripheral monocyte MMP-9 was measured by RT-PCR and Western blot. RESULTS： The concentration of serum MMP-9 was dose-dependen lowered by pioglitazone treatment. Expression of peripheral monocyte MMP-9 was also down-regulated by pioglitazone treatment. CONCLUSION： Results indicate that pioglitazone may have some protective cardiovascular effect in addition to a hypoglycemic effect.
出处
《心脏杂志》
CAS
2010年第1期44-47,共4页
Chinese Heart Journal
